The α4β7+ ALS IgA responses post-challenge showed similar trends to the α4β7+ ALS IgG responses, with protected vaccinees having a higher magnitude of α4β7+ ALS IgA responses on day 7 compared to day 63 while oral challenge increased the α4β7+ ALS IgA responses in unprotected vaccinees (Fig. 4b). The gene discussed is CD79A; the disease is amyotrophic lateral sclerosis.